Quantcast
Home > Quotes > FENC

Fennec Pharmaceuticals Inc. Common Stock (FENC) Quote & Summary Data

FENC 
$6.1
*  
0.05
0.83%
Get FENC Alerts
*Delayed - data as of Dec. 12, 2018  -  Find a broker to begin trading FENC now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    FENC Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
17
Today's High / Low
$ 6.52 / $ 5.975
Share Volume
68,745
50 Day Avg. Daily Volume
71,059
Previous Close
$ 6.05
52 Week High / Low
$ 14.9862 / $ 5.84
Market Cap
116,535,400
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.68

Intraday Chart

Shares Traded

Share Volume:
68,745
50 Day Avg. Daily Volume:
71,059

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.52

Trading Range

The current last sale of $6.10 is 4.45% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 6.52 $ 14.9862
 Low: $ 5.975 $ 5.84

Company Description (as filed with the SEC)

Fennec Pharmaceuticals Inc. ("Fennec," the "Company," "we," "us," or "our") is a biopharmaceutical company focused on the development of PEDMARKTM (a unique formulation of Sodium Thiosulfate ("STS")) for the prevention of platinum-induced ototoxicity in pediatric cancer patients. We incorporated under the Canada Business Corporations Act ("CBCA") in September 1996. Effective on August 25, 2011, the Company continued from the Canada Business Corporations Act to the Business Corporations Act (British Columbia) (the "Continuance"). The Continuance was approved by the shareholders of Fennec at the Company's June 2011 Annual and Special Meeting and by resolution of the Board of Directors on August 10, 2011. We have three wholly-owned subsidiaries: Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, and Cadherin Biomedical Inc., a Canadian company. With the exception of Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.  ... More ...  


Risk Grade

Where does FENC fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 6.11
Open Date:
Dec. 12, 2018
Close Price:
$ 6.05
Close Date:
Dec. 12, 2018

Consensus Recommendation

Analyst Info